SCHEMBL7834412

SCHEMBL7834412

O=C(O)CCCCC(=O)CCCCC(=O)O

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.79
TSHR P16473 4/20 0.73
NFKB1 P19838 2/20 0.73
PMP22 Q01453 1/20 0.73
KMT2A Q03164 2/20 0.70
MAPT P10636 1/20 0.70
SLC22A6 Q4U2R8 2/20 0.67
FOLH1 Q04609 1/20 0.67
GPR84 Q9NQS5 4/20 0.58
FFAR1 O14842 2/20 0.58
FFAR4 Q5NUL3 2/20 0.58
AKR1B1 P15121 1/20 0.58
CYP2D6 P10635 1/20 0.58
CAMK2A Q9UQM7 1/20 0.56
PPARG P37231 4/20 0.55
PPARD Q03181 4/20 0.55
PPARA Q07869 4/20 0.55
HDAC11 Q96DB2 3/20 0.55
ALDH1A1 P00352 2/20 0.55
TDP1 Q9NUW8 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8843654 0.97 TSHR (0.80) LMNATSHRNFKB1PMP22KMT2A
SCHEMBL11316452 0.97 TSHR (0.80) LMNATSHRNFKB1PMP22KMT2A
SCHEMBL2349616 0.97 TSHR (0.80) LMNATSHRNFKB1PMP22KMT2A
SCHEMBL25209921 0.97 TSHR (0.80) LMNATSHRNFKB1PMP22KMT2A
SCHEMBL15013307 0.97 TSHR (0.80) LMNATSHRNFKB1PMP22KMT2A
SCHEMBL25215828 0.97 TSHR (0.80) LMNATSHRNFKB1PMP22KMT2A
SCHEMBL9680290 0.97 TSHR (0.80) LMNATSHRNFKB1PMP22KMT2A
SCHEMBL8761235 0.97 TSHR (0.80) LMNATSHRNFKB1PMP22KMT2A
SCHEMBL2580866 0.97 TSHR (0.80) LMNATSHRNFKB1PMP22KMT2A
SCHEMBL8843674 0.97 TSHR (0.80) LMNATSHRNFKB1PMP22KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115139-A1 Amino Acid-Containing Ionizable Lipids for the Delivery of Therapeutic Agents NANOVATION THERAPEUTICS INC. (CA) 2026-04-30 US disclosed
EP-4594293-A1 AMINO ACID-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF THERAPEUTIC AGENTS Nanovation Therapeutics Inc. (CA) 2025-08-06 EP disclosed
WO-2025035202-A1 IONIZABLE LIPIDS COMPRISING MACROCYCLIC RINGS FOR THE DELIVERY OF THERAPEUTIC AGENTS NANOVATION THERAPEUTICS INC. (CA) 2025-02-20 WO disclosed
WO-2024065041-A1 SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF THERAPEUTIC AGENTS NANOVATION THERAPEUTICS INC. (CA) 2024-04-04 WO disclosed
WO-2024065043-A1 AMINO ACID-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF THERAPEUTIC AGENTS NANOVATION THERAPEUTICS INC. (CA) 2024-04-04 WO disclosed
US-20090306134-A1 Muscarinic receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC 2009-12-10 US disclosed
US-20090306134-A1 Muscarinic receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC 2009-12-10 US disclosed
US-20090111737-A1 Novel antibacterial agents THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC 2009-04-30 US disclosed
US-20090111737-A1 Novel antibacterial agents THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC 2009-04-30 US disclosed
US-7456203-B2 Muscarinic receptor antagonists THERAVANCE, INC. (US) 2008-11-25 US disclosed
EP-0347687-B1 Biodegradable polyamide, films and products obtained from said polyamide and process for its preparation SNIA TECNOPOLIMERI (IT) 1995-09-06 EP disclosed
US-5140095-A Incorporating a ketodicarboxylic acid SNIA TECNOPOLIMERI S.P.A. (IT) 1992-08-18 US disclosed
EP-0169033-B1 INHIBITORS OF SLOW REACTING SUBSTANCE OF ANAPHYLAXIS SCHERING CORPORATION (US) 1992-02-12 EP disclosed
US-4988716-A Inhibitors of slow reacting substance of anaphylaxis SCHERING CORPORATION (US) 1991-01-29 US disclosed
WO-1989012656-A1 BIODEGRADABLE POLYAMIDE, FILMS AND PRODUCTS OBTAINED FROM SAID POLYAMIDE AND PROCESS FOR ITS PREPARATION SNIA TECNOPOLIMERI S.P.A. (IT) 1989-12-28 WO disclosed
EP-0347687-A1 Biodegradable polyamide, films and products obtained from said polyamide and process for its preparation CAFFARO S.p.A. (IT) 1989-12-27 EP disclosed
US-4889873-A Inhibitors of slow reacting substance of anaphylaxis SCHERING CORPORATION (US) 1989-12-26 US disclosed
US-4798842-A Inhibitors of slow reacting substance of anaphylaxis SCHERING CORPORATION (US) 1989-01-17 US disclosed
US-4758594-A Inhibitors of slow reacting substance of anaphylaxis SCHERING CORPORATION (US) 1988-07-19 US disclosed
EP-0169033-A2 Inhibitors of slow reacting substance of anaphylaxis SCHERING CORPORATION (US) 1986-01-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260115139-A1 Amino Acid-Containing Ionizable Lipids for the Delivery of Therapeutic Agents SLC43A1, SLC7A1, SLC7A5 LMNA 556/4885TSHR 1219/4885NFKB1 3789/4885
US-20090306134-A1 Muscarinic receptor antagonists CHRM3, CHRM5, CHRM2 LMNA 4772/4885TSHR 275/4885NFKB1 2313/4885
US-20090111737-A1 Novel antibacterial agents ENGASE, PGLS, PEPD LMNA 3115/4885TSHR 4185/4885NFKB1 3548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.